Staging is a standard way to determine the severity of the cancer. Staging is a stan prostate cancer survival rate can then be estimated after the cancer stage has been discovered. Prostate Cancer Staging The staging system for prostate cancer is based on American Joint Committee on Cancer (AJCC) TNM system. TNM itself stands for Tumor, Node and Metastasis. Metastatic prostate cancer survival rate in every patient can be different and the TNM system is the first step to figure out the patient’s prognosis. There are five important things TNM system can tell. The T category will tell about the extent of the tumor while the N category is used to tell whether the cancer has affected surrounding lymph nodes or not. Meanwhile, the M will tell whether or not the cancer has metastasized to other organs. In addition, the system also will give information about the patient’s PSA level and the likelihood for the cancer to spread based on the Gleason score. After collecting those five information, the doctor will be able to tell the stage and metastatic prostate cancer survival rate to the patients. Survival Rate of Prostate Cancer Based on the Stages Stage 1 The size of the tumor is small and it is localized inside the prostate. Stage 1 prostate cancer often doesn’t show any symptoms and even doesn’t show up in imaging tests. At this stage, the 5-year survival rate is close to 100%. Stage 2 At this point, the patient might start feeling some symptoms. Furthermore, imaging tests and other examinations might be able to detect the cancer. Just like Stage 1, the cancer has not spread outside the prostate, however it is possible that the cancer will grow more rapidly. The 5-year survival rate for Stage 2 is still around 100%. Stage 3 In this stage, the cancer might start spreading to surrounding lymph nodes and seminal vesicles. Since the cancer has spread, the 5-year survival rate decreases to around 95%. Stage 4 Stage 4 is also called metastatic cancer because the cancer has spread outside of the prostate to the other organs. Besides surrounding lymph nodes, metastatic prostate cancer often spreads to the lungs, bones and also liver. When the cancer has metastasized to other organs, the 5-year survival rate will go down to 29%. Besides estimating the survival rate, staging is also used to determine which treatments will be more suitable for the patients. Because prostate cancer is a slow growing cancer, watchful waiting might be enough for Stage 1 patients. Meanwhile, patients with Stage 4 metastatic prostate cancer might have to resort to more aggressive treatment methods.